Nivolumab vs Upadacitinib
Nivolumab vs Upadacitinib: Overview
This comparison examines the pharmacological differences between Nivolumab and Upadacitinib.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Upadacitinib: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.
Pharmacokinetics
Half-life: Nivolumab — 27 days; Upadacitinib — 9-14 hours.
Chemical Properties
Molecular Formula: Upadacitinib — C17H19F3N6O.
Molecular Weight: Upadacitinib — 380.3700 g/mol.
Type: Nivolumab — Antibody; Upadacitinib — Small molecule.